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Abstract
Background: High rates of food insecurity, obesity and obesity-related comorbidities in ageing South African (SA)
women may amplify the risk of developing sarcopenic obesity. This study aimed to investigate the prevalence and
correlates of sarcopenic obesity and its diagnostic components [grip strength, appendicular skeletal muscle mass
(ASM) and body mass index (BMI)] in older SA women from a low-income setting.
Methods: This cross-sectional study recruited black SA women between the ages of 60–85 years (n = 122) from a
low-income community. Testing included a fasting blood sample (markers of cardiometabolic risk, HIV), whole body
and regional muscle and fat mass (dual-energy absorptiometry x-ray), anthropometry, blood pressure, functional
movement tests, current medication use, demographic and health questionnaires, physical activity (PA;
accelerometery), household food insecurity access scale, and a one-week quantified food frequency questionnaire.
Foundation for the National Institutes of Health (FNIH) criteria (grip strength and ASM, adjusted for BMI) were used
to classify sarcopenia. Participants with sarcopenia alongside a BMI of > 30.0 kg/m2 were classified as having
sarcopenic obesity. Prevalence using other criteria (European Working Group on Sarcopenia in Older People, Asian
Working Group for Sarcopenia and the International Working Group for Sarcopenia) were also explored.
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Results: The prevalence of sarcopenia was 27.9%, which comprised of sarcopenia without obesity (3.3%) and
sarcopenic obesity (24.6%). Other classification criteria showed that sarcopenia ranged from 0.8–14.7%, including
0.8–9.8% without obesity and 0–4.9% with sarcopenic obesity. Using multivariate-discriminant analysis (OPLS-DA)
those with sarcopenic obesity presented with a descriptive profile of higher C-reactive protein, waist circumference,
food security and sedentary time than women without sarcopenic obesity (p = 0.046). A similar profile described
women with low BMI-adjusted grip strength (p < 0.001).
Conclusions: The majority of women with sarcopenia were also obese (88%). We show a large discrepancy in the
diagnostic criteria and the potential for significantly underestimating the prevalence of sarcopenia if BMI is not
adjusted for. The main variables common to women with sarcopenic obesity were higher food security, lower PA
and chronic inflammation. Our data highlights the importance of addressing obesity within these low-income
communities to ensure the prevention of sarcopenic obesity and that quality of life is maintained with ageing.
Keywords: Sarcopenia, Physical activity, Ageing, Diet, Inflammation, Food security
Background
Economic and social transition in low-middle income
countries (LMIC) has seen substantial increases in life
expectancy alongside increasing rates of obesity and car-
diometabolic disease [1]. Accordingly, age-related dis-
eases such as sarcopenia are of increasing interest due to
the impact on quality of life, frailty, falls and mortality
[2–4]. Sarcopenia is operationally defined as low muscle
mass and function, and has been shown to increase risk
for developing functional limitations and physical dis-
abilities, as defined by difficulty in performing daily ac-
tivities [5]. Therefore, reversing, delaying, and/or
preventing the onset of sarcopenia and maintaining
functional mobility is paramount to ensuring quality of
life with ageing [6]. However, data on the prevalence
and understanding potential determinants of sarcopenia
in LMIC's are scarce [7].
There are many different and population specific cri-
teria for the classification of sarcopenia, including the
European Working Group on Sarcopenia in Older
People (EWGSOP [8, 9]), Asian Working Group for Sar-
copenia (AWGS) [10], International Working Group for
Sarcopenia (IWGS) [11] and The Foundation for the Na-
tional Institutes of Health (FNIH) [7]. Development of
the FNIH criteria included data in African Americans
from a variety of income levels and has been previously
used in studies of women from sub-Saharan Africa [7].
Importantly, the FNIH criteria incorporate cut-points
for grip strength and appendicular skeletal muscle mass
(ASM) adjusted for body mass index (BMI), which may
be an optimal approach when classifying sarcopenia in
individuals with obesity [12]. Notably, the criterion rec-
ommended for defining clinically meaningful low lean
body mass is adjusted for BMI (ASMBMI) [12]. More-
over, individuals with obesity, regardless of age, have a
greater absolute maximum muscle strength compared to
individuals without obesity; however, when maximum
muscular strength is normalised to body mass, individ-
uals with obesity appear weaker [6]. Therefore, a similar
approach by FNIH has identified clinically significant,
gender-specific cut-points for BMI adjusted strength
(Grip StrengthBMI) [12, 13].
This is particularly relevant when assessing sarcopenia
in LMIC's that present with an increasing double burden
of malnutrition, which refers to the co-existence of un-
dernutrition and overweight/obesity [14]. In particular,
SA women have the highest prevalence of overweight
and obesity in sub-Saharan Africa (68%) [15, 16], which
is occurring simultaneously with 64% of households ex-
periencing food insecurity [17]. Furthermore, food inse-
curity is an upstream determinant of behaviours such as
diet and physical activity (PA), which are in turn associ-
ated with an increased risk of overweight and obesity
[17, 18]. The presence of obesity coupled with sarcope-
nia has recently been termed ‘sarcopenic obesity’ or ‘sar-
cobesity’, and has been shown to exacerbate
cardiometabolic risk and functional limitations [6, 19].
The determinants of sarcopenia and sarcopenic obesity
is complex and incorporates multiple factors, such as
physical inactivity, low protein intake, chronic systemic
inflammation, insulin resistance and fat infiltration into
the muscle [20–23]. Previous studies examining these
determinants have occurred in cohorts from high-
income countries [7–9, 11, 23–25], with little data avail-
able from low-income settings [7, 26, 27]. It is antici-
pated that high rates of food insecurity, obesity and
obesity-related comorbidities in ageing SA women may
amplify the risk of developing sarcopenic obesity. How-
ever, socioeconomic status, PA, diet, and cardiometa-
bolic risk separating those with and without sarcopenia
or sarcopenic obesity have not been previously explored
in African women. Using a cross-sectional design, this
study aimed to compare the prevalence of sarcopenia
using different criteria and investigate the correlates of
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sarcopenic obesity and its diagnostic components (grip




A convenience sample of community dwelling older
women (n = 122) were recruited from a low-income,
urban SA setting with a demographic profile composing
of black South Africans [28]. Women were recruited
from senior community groups/clubs and included those
between the ages of 60–85 years, living independently
(living in their own household or living with family) and
who were ambulatory. One participant per household
was recruited. Participants were excluded if they had any
physical disability or condition that prevented them
from completing the functional tests. In the context of
the South African population, an older adult was classi-
fied as > 60 years based on the classification from the
United Nations and due to the low life-expectancy of
65.1 years for South African adults (68.3 and 61.9 years
for women and men, respectively) [29, 30].
Study design and ethical consideration
For this cross-sectional observational study, clinical re-
search workers visited the community centres for con-
sent and screening after which participants attended the
university-based laboratory on two separate occasions
with one week between testing sessions. The first testing
session included fasting blood sample and HIV testing,
body composition, blood pressure, functional movement
tests, and sociodemographic and health questionnaires.
Participants were fitted with accelerometers and asked
to complete sleep diaries for the following week, which
were collected at the second testing session. Participants
also completed a nutritionist-administered one-week
food frequency questionnaire. This study was approved
by the Human Research Ethics Committee of the Faculty
of Health Sciences at the University of Cape Town
(HREC REF:095/2018), and the NHS, Invasive or Clinical
Research Committee at the University of Stirling (NICR:
17/18). All participants provided written and verbal con-
sent prior to testing procedures, including consent for
HIV testing with counsellor support.
Classification of sarcopenia and sarcopenic obesity
The FNIH Sarcopenia Project used an evidence-based
approach to develop criteria for sarcopenia classification
[12]. Recommendations for cut-points for low muscle
strength and low lean muscle mass included Grip
strengthBMI of < 0.56, and ASMBMI of < 0.512, respect-
ively. Participants presenting with both low Grip
strengthBMI and ASMBMI were classified as sarcopenic.
Participants classified with sarcopenia alongside a BMI
of > 30.0 kg/m2 were classified as having sarcopenic
obesity [31]. The variability in the prevalence of sarcope-
nia and sarcopenic obesity based on the classification
criteria of EWGSOP [8], EWGSOP-2 [9], AWGS [10],
IWGS [11] and a criterion for ASMI in SA women [26]
were also explored in this cohort (Table 1).
Components and correlates of sarcopenia and
sarcopenic obesity
Body composition
Body mass (BW-150, NAGATA, Tainan, Taiwan) and
stature (3PHTROD-WM, Detecto, Missouri, USA) were
measured in lightweight clothing for the calculation of
BMI and used to classify obesity (> 30.0 kg/m2) [32].
Waist circumference (WC) at the umbilicus, and hip cir-
cumference (HC) at the largest protrusion of the but-
tocks, were measured using a metal anthropometric tape
measure (CESCORF, Brazil). Circumferences were mea-
sured over the naked skin and noted to the nearest 0.1
cm. Circumferences were used to calculate waist to hip
Table 1 Classification of participants according to different sarcopenia classification criteria
Variables FNIH EWGSOP EWGSOP2 AWGS IWGS SA
Low ASMI (kg/m2) 27 (22.1) 27 (22.1) 17 (13.9) 16 (13.1) 3 (2.5)a
Low grip strength (kg) 63 (52.1) 24 (19.8) 25 (20.5) – –
Low gait speed (m/sec) 2 (1.6) 2 (1.6) 7 (5.7) 7 (5.7)
Low ASMBMI 58 (47.5)
Low grip strengthBMI 56 (45.9)
Sarcopenia Classification
No sarcopenia 88 (72.1) 104 (85.3) 113 (92.6) 115 (94.3) 121 (99.2)
Sarcopenia 34 (27.9) 18 (14.7) 9 (7.4) 7 (5.7) 1 (0.8)
Sarcopenic non-obese 4 (3.3) 12 (9.8) 5 (4.1) 5 (4.1) 1 (0.8)
Sarcopenic obesity 30 (24.6) 6 (4.9) 4 (3.3) 2 (1.6) 0 (0)
Data reported as n(%). European Working Group on Sarcopenia in Older People, EWGSOP [8, 9]; The Foundation for the National Institutes of Health, FNIH [7];
Asian Working Group for Sarcopenia, AWGS [10]; International Working Group for Sarcopenia, IWGS [11]; South Africa, SA (Criteria for low muscle mass) [26]
a No participants had low ASMI and obesity
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ratio (WHR), with abdominal obesity classified as WC >
80 cm and WHR > 0.85 [32].
Whole body composition was measured using dual en-
ergy x-ray absorptiometry (DXA; Discovery- W®, version
12.7.3.7, Hologic, Bedford, MA, USA) according to
standard procedures. Sub-total (excluding the head) fat
mass (FM) and fat-free soft tissue mass (FFSTM) were
used for all analyses. Appendicular skeletal muscle mass
(ASM) was calculated using the sum of FFSTM (kg) of
both legs and arms, which was further adjusted for stat-
ure (ASMI; kg/height (m2)) and BMI (ASMBMI). DXA-
derived regional body fat distribution, including android
and gynoid were determined as previously described [33]
and expressed as a percentage of subtotal FM. Peripheral
(appendicular) fat (kg) was calculated as the sum of FM
of both legs and arms, which was further divided by
ASM to calculate peripheral fat/ASM ratio. Subcutane-
ous (SAT) and visceral (VAT) adipose tissue areas were
estimated as described previously [34] and used to calcu-
late VAT/SAT ratio. Bone mineral density was quanti-
fied using DXA at the spine (lumbar vertebrae L1-L5),
total hip and femoral neck and World Health Organisa-
tion classification (t-score < − 2.5) was used to determine
those with osteoporosis (Low t-score at > 1 site) [35].
Sociodemographic and health questionnaires
Sociodemographic questionnaire included, estimated
household monthly food costs, measures of household
asset index (total of 11 assets that included the
ownership of electrical appliances, computers, internet
and/or motor vehicles), housing density (ratio of the
number of people living in the house divided by the
number of rooms) and the number of children (< 18
years) financially supported by the participants.
Participants brought to the study site all medication/s
currently prescribed to them for recording and was
used to identify disease prevalence of hypertension,
dyslipidemia, diabetes, arthritis, and HIV. Disease
prevalence for cancer and tuberculosis was obtained
using self-reported diagnosis and medication history
of the disease and osteoporosis was identified from
bone mineral density scans (DXA). Notably, through
verbal communication with participants we identified
a low reliability in the self-reported patient history of
several chronic conditions (i.e. stroke, heart failure
and coronary artery disease), which are not reported
in the current study. Multi-morbidity was classified as
having 2 or more of the aforementioned listed dis-
eases. All participants underwent a rapid HIV test,
due to previously identified associations between HIV
and premature ageing, sarcopenia, obesity and visceral
adiposity [36, 37]. Pre and post-test counselling were
completed by a trained HIV counsellor and if the
participant was HIV positive (known or unknown)
they continued in the study and were referred to a
local clinic for follow-up testing and counselling. All
information on current and past smoking (duration of
smoking and number of daily cigarettes) behaviours
was obtained. Participants were also asked if they had
fallen in the past year. A fall was defined as ‘any time
you unexpectedly (or unintentionally) landed on the
floor or ground’ [38]. Participants further completed a
Household Food Insecurity Access Scale (HFIAS),
which consists of nine questions about worry,
availability and accessibility of foods for the house-
hold during the previous 30 days [39]. Total HFIAS
ranges from 0 (food security) to 27 (maximum food
insecurity).
Components of metabolic syndrome, inflammation, iron
and vitamin-D
Participants arrived at the laboratory at 09:00 following an
overnight fast (10–12 h). A fasting venous blood sample
was collected for the analysis of cardiometabolic risk
markers. Specifically, components of metabolic syndrome,
including glucose (enzymatic method with hexokinase,
Cobas Analyzer, Roche Diagnostics, Basel, Switzerland),
high-density lipoprotein (HDL) cholesterol, and triglycer-
ide (enzymatic colorimetric test, Cobas Analyzer) concen-
trations were analysed. Metabolic syndrome was
determined if participants had three or more components
using the 2009 harmonized criteria [40]. These compo-
nents included: elevated waist circumference (≥80 cm in
women), elevated triglycerides (≥1.7mmol/L and/or using
cholesterol lowering medication), reduced HDL choles-
terol (< 1.3 mmol/L in women), elevated blood pressure
(≥130mmHg for systolic and/or ≥ 85mmHg for diastolic
and/or using blood pressure medication), and elevated
glucose (≥5.6mmol/L and/or using diabetes medication).
Vitamin- D 25 OH (electrochemiluminescence binding
assay, Cobas Analyzer), C-Reactive protein (CRP) (high-
sensitivity, particle enhanced immunoturbidimetric assay,
Cobas Analyzer) and ferritin (immunoassay, Cobas) were
analysed. An acute inflammatory response was suspected
when a high ferritin level (> 150 ng/mL) coincided with
high CRP (> 20mg/dL) and these data (n = 11) were re-
moved from analyses [41].
Blood pressure was measured 3 times at 1-min inter-
vals using an appropriately sized cuff and an automated
blood pressure monitor (Omron 711, Omron Health-
care, Hamburg, Germany), after participants had rested
in a seated position for 30 min. The mean of the two
measurements is presented.
Functional movement tests
All functional movement tests were conducted on the
same day and by the same research assistant. All tests
were conducted in the order reported below.
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Strength
Grip strength (kg) was measured in a seated position on
the non-dominant hand using a hand dynamometer
(T.K.K. 5401, Grip-D, Takei, Tokyo, Japan). The
measures were taken with the arm static and elbow by
the side in a right-angle position. The test was repeated
3 times with a 1-min rest between tests. The maximum
score was used in the analysis [42].
Gait speed
Participants were required to complete a 10-m walk test
which involved walking ‘at a fast pace’ between two
markers that were set up 14 m apart. Tape was placed
on the ground at the 2-m and 12-m mark in order to ex-
clude the acceleration and deceleration phase to ensure
a measure of ‘steady state’ walking was obtained [43].
The time taken to walk between the 2- and 12-m
markers was recorded, and the test was repeated twice
with a 1-min rest between tests. The mean score was
used in the analysis (m/s).
Agility/dynamic balance
The 3-m timed-up and go test was completed by meas-
uring the time taken to get up from a seated position
(without using arms for assistance), walk around a
marker at 3 m, and return to the seated position. This
test was repeated twice with a 1-min rest between tests.
The fastest time was used in the analysis (seconds) [44].
Aerobic endurance
The 6-min walk test was conducted once to measure the
number of metres covered by walking in a 6-min time
period. The research assistant used a stopwatch and
walked quietly behind the participant during the test to
mark and monitor the distance covered. Participants
walked in a 20 × 5m rectangle [43].
Physical activity, sleep and sedentary behaviour
Physical activity, sleep and sedentary behaviour were
measured simultaneously with an Actigraph (GTX3+,
ActiGraph LLC, Pensacola, Florida) and ActivPAL (PAL
Technologies Ltd., Glasgow, Scotland). Both accelerome-
ters were worn for seven consecutive 24-h days. The
Actigraph was attached to the waist with a lightweight
belt and the ActivPAL was worn on the mid anterior
right thigh. Participants completed a sleep diary to rec-
ord wake and sleep times over the 7-day period. Acti-
graph data was analysed (ActiLife, version 6) with valid
wear defined as 600min of waking wear time per day for
a minimum of four days. Troiano cut-points were used
to define total PA (> 100 cpm), light PA (100–2019 cpm)
and moderate to vigorous physical activity (MVPA; >
2020 cpm) [45]. ActivPAL data were analysed (CREA
beta-algorithm, PAL analysis, Version 8.10.8.32) with all
participants presenting with a minimum of seven con-
secutive 24-h days. Wear time included a 24-h protocol,
allowing for 4 h of non-wear time, minimum of 10 s
non-upright and upright periods. Daily step count and
number of sit to stand transitions, time spent upright
(total of standing and stepping time), standing, stepping
sitting, napping (secondary lying time), sleeping (primary
lying time), total time spent in sedentary bouts of more
than 30 and 60min are reported, and daily energy ex-
penditure (calories) was calculated by multiplying daily
metabolic equivalent of task (MET) by body weight (kg).
Dietary intake
A nutritionist administered a 7-day quantified food
frequency questionnaire (QFFQ) for each participant.
Food portion sizes were estimated using household
utensils, food containers and packaging, three-
dimensional sponge models and “dish-up and meas-
ure”. Amounts reported in household measures or vol-
ume were converted to grams using the SA Medical
Research Council (SAMRC) Food Quantities Manual
for SA [46]. Food intake was converted to energy and
macronutrients (fats, carbohydrates, protein (animal
and plant), fibre, and added sugar) using the SA food
composition database [47]. Food consumed during the
7-day reference period for the QFFQ were categorized
into 12 food groups and expressed as a % of energy in-
take (%EI), based on a recent SA study [48]. The food
groups included, fruits, vegetables, cooked porridge,
starchy grains, legumes, nuts and seeds, milk and dairy
products, animal source foods, fats and oils, sugar and
sugary foods, savoury snacks, dishes and sauces and
alcohol. Dietary data was removed if the participant
reported below 4000 kJ per day (n = 19 removed).
Sample size calculation and statistical analyses
Based on methodology in Kruger et al. [26] we used
G*Power 3.1 to estimate sample size for a multiple
regression model with a medium effect size (F tests –
Linear multiple regression: Fixed model, R2 increase at
95% power, medium effect size = 0.15), which gave a
sample size of n = 107.
Data were expressed as mean ± standard deviation
(SD) or median interquartile range (IQR - 25th–75th
percentile) depending on the normality of continuous
variables. Normality was tested using Shapiro-Wilks test
and skewed data were log transformed before analysis.
Data was analysed using IBM SPSS statistics (Version
26, Statistical Package for the Social sciences, Chicago,
IL, USA). P values are uncorrected for multiple testing
and are reported, with significance set at p < 0.05.
All outcomes were firstly compared univariately
between groups (with and without sarcopenia) using an
independent t-test or Mann-Whitney U test for normally
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distributed and skewed data, respectively. Secondly, to
investigate the differences in lifestyle behaviors (diet and
PA), components of metabolic syndrome, body compos-
ition, functional movement and socioeconomic status
between those with and without sarcopenic obesity, we
explored the data using a multivariate analysis. Firstly, a
principle component analysis identified that there were
no outliers. Secondly, orthogonal partial least squares
discriminant analysis (OPLS-DA; SIMCA v.15.2
(Sartorius, Umetrics, Umea, Sweden) models were calcu-
lated to explore the differences between those with and
without sarcopenic obesity. OPLS-DA is a supervised
modelling approach that uses a predefined binary vari-
able as the outcome (2 class model that describes those
with and without sarcopenic obesity). Finally, two fur-
ther OPLS models were conducted using grip
strengthBMI and ASMBMI as continuous predictors. Both
OPLS and OPLS-DA models summarise the largest sys-
tematic variation in the dataset into 1 latent variable
(OPLS as one constant predictor variable and OPLS-DA
as a 2-class model). These methods are highly suitable
for a large number of highly correlated variables and
provides information on the variables that have the
largest discriminatory power [49]. To prevent overfitting
of models, the models were validated based on ANOVA
of the cross-validated OPLS-DA scores (CV-ANOVA)
for significance testing [50]. A validated and significant
model was considered with a CV-ANOVA of p < 0.05.
Variables in each model were considered significant
when fulfilling the statistical significance criteria using
post-hoc linear regression on loadings calculated from
the validated OPLS-models on a 95% confidence level
[51]. All data in the OPLS models are reported as
loading weight (w) with 95% confidence intervals, which
describes the contribution of each listed variable (X
variable) to the model. Variables with large w’s (positive
or negative) are highly correlated with the Y variable




The application of different sarcopenia criteria is pre-
sented in Table 1. The FNIH criteria for sarcopenia was
used to classify participants with sarcopenia (27.9%),
which comprised of sarcopenia without obesity (3.3%)
and sarcopenic obesity (24.6%). Using other sarcopenia
classification criteria, the prevalence of sarcopenia
ranged from 0.8–14.7%, which included 0.8–9.8% with-
out obesity and 0–4.9% with sarcopenic obesity.
We then compared functional and body composition
characteristics of the women with and without sarcope-
nia based on the FNIH criteria (Table 2). The majority
(n = 87, 71%) of the total sample were classified as obese,
with 88% (n = 30) of participants with sarcopenia and
65% (n = 57) of participants without sarcopenia being
obese (p = 0.005). Accordingly, variables relating to total
adiposity and body fat distribution were higher in those
with sarcopenia (p < 0.05). Functional movement tests
showed lower grip strength, gait speed and endurance
(6-min walk test) in those with sarcopenia (p < 0.05).
Univariate analysis shows that the majority of the
cohort (73%) presented with metabolic syndrome and
the prevalence tended to be higher in women with sar-
copenia (Table 3). Furthermore, the sarcopenic group
had higher CRP and lower iron levels (ferritin) compared
to those without sarcopenia (p < 0.05). Participants with
sarcopenia supported more children (p < 0.05) and few
women in the cohort were previous (n = 5) or current
smokers (n = 11).
Physical activity, sedentary behaviour and dietary
intake data are shown in Table 3. Univariate analysis
showed that women with sarcopenia presented with a
lower daily step count, stepping time, and sit to stand
transitions than women without sarcopenia (p < 0.05).
The mean macronutrient consumption for the whole
cohort comprised of 64.8 ± 7.2%EI carbohydrates, 12.3 ±
2.1%EI protein and 21.2 (17.5–25.1) %EI fat. Further, the
dominant food groups consumed were starchy grains
(31.1 ± 11.4%EI), and sugar and sugary foods (14.9
(10.1–20.8) %EI). There were no differences in dietary
intake between the women with sarcopenia and those
without.
The prevalence of falls and multimorbidity are
presented in Table 4. Falls in the last year were reported
by 38% (n = 46) of women and this did not differ be-
tween those with and without sarcopenia (p > 0.05).
Ninety one percent (n = 111) of women had multimor-
bidity (> 2 diseases) and this did not statistically differ by
group (p > 0.05). Women with sarcopenia had a higher
prevalence of hypertension (97%, n = 33) compared to
women without sarcopenia (82%, n = 72; p < 0.05).
Correlates of sarcopenic obesity and its components
using OPLS modelling
As the majority of participants with sarcopenia (FNIH
criteria) were also obese we explored correlates of sarco-
penic obesity. OPLS-DA modelling was used to deter-
mine a profile of variables that discriminated between
non-sarcopenic and sarcopenic obese individuals (CV-
ANOVA p < 0.001; Fig. 1). Figure 1 (a) presents individ-
ual variability based on group classification (b) and the
variables that significantly discriminated between groups.
This model presents behavioural (dietary intake, PA and
sedentary behaviour), sociodemographic and phenotypic
characteristics (components of metabolic syndrome,
VAT/SAT ratio and functional movement) to assist in
developing a profile in SA women that may identify
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those with sarcopenic obesity. Interestingly, those with
sarcopenic obesity supported more children and were
more food secure. Unsurprisingly, several metabolic syn-
drome components (waist circumference and triglycer-
ides), alongside chronic systemic inflammation (CRP)
were higher in those with sarcopenic obesity. In terms of
the functional movement tests, gait speed was not a sig-
nificant contributor to the model, but rather those with
sarcopenic obesity had lower cardiovascular fitness (6-
min walk test), daily step count, stepping time, light PA,
sit to stand transitions, and daily energy expenditure.
Time spent sitting for more than 30 and 60-min bouts
was significantly higher in those with sarcopenic obesity.
Interestingly, there were no dietary intake characteristics
that significantly contributed to the sarcopenic obesity
profile.
The two main components for the FNIH classification
of sarcopenia used in the current study include, ASMBMI
and grip strengthBMI. To understand the contribution of
each correlate to the latent variable we generated two
OPLS models with ASMBMI and grip strengthBMI as con-
tinuous predicted variables. Notably, there was no sig-
nificant OPLS model profile that correlated with
ASMBMI (CV-ANOVA p = 1.00). In contrast, Fig. 2 (a)
shows individual variability in the model and identifies
participants with low grip strengthBMI based on the
FNIH criteria. The significant cross-validated model
(CV-ANOVA p < 0.001; Fig. 2 b) identifies that a higher
asset index was the only significant sociodemographic
component that was associated with lower grip
strengthBMI. In terms of the components of metabolic
syndrome, a lower grip strengthBMI was associated with
a higher waist circumference, blood pressure, triglycer-
ides and systemic inflammation (CRP). Those with a
lower grip strengthBMI had lower gait speed, agility and
balance (TUG) and cardiovascular fitness (6-min walk
Table 2 Body composition, fat distribution and functional movement characteristics of the cohort and those with and without
sarcopenia
Variables Cohort (n = 122) No sarcopenia (n = 88) Sarcopenia (n = 34) P value
Age (Years) 67 (64–71) 67 (64–71) 68 (64–71) 0.943
Height (cm) 155.8 ± 6.1 157.0 ± 6.1 152.9 ± 4.9 0.001
Weight (kg) 81.6 (69.0–98.9) 77.1 (66.6–91.8) 92.4 (81.7–108.9) 0.002
BMI (kg/m2) 33.1 (29.0–40.1) 31.9 (28.3–35.6) 39.3 (34.3–45.4) < 0.001
Waist-to-hip ratio (cm) 0.95 (0.87–0.10) 0.95 (0.88–0.99) 0.96 (0.84–1.0) 0.945
Body fat-mass (kg) 36.6 (28.2–47.6) 32.7 (26.0–41.9) 47.4 (37.7–55.9) < 0.001
Body fat-mass (%) 48.6 ± 5.9 47.0 (43.8–50.6) 55.0 (51.0–57.0) < 0.001
FFSTM (kg) 36.7 (32.6–41.3) 35.7 (32.8–41.1) 37.5 (32.3–42.9) 0.733
Android (%) 8.6 ± 1.4 8.6 ± 1.5 8.7 ± 1.5 0.880
Gynoid (%) 16.0 ± 2.5 16.1 ± 2.5 15.6 ± 2.2 0.260
VAT (cm2) 196.3 ± 74.5 183.4 ± 75.0 229.0 ± 65.0 0.002
SAT (cm2) 477.9 ± 138.2 441.2 ± 132.9 569.7 ± 105.6 < 0.001
VAT/SAT ratio 0.40 (0.32–0.48) 0.42 ± 0.13 0.40 ± 0.10 0.628
ASM (kg) 16.5 (14.7–19.6) 16.5 (14.6–19.5) 17.4 (15.0–20.2) 0.455
ASMI (kg/m2) 6.9 (6.1–7.9) 6.8 (6.0–7.5) 7.4 (6.2–8.8) 0.036
ASMBMI (kg/m
2) 0.514 (0.459–0.578) 0.54 (0.50–0.67) 0.45 (0.42–0.48) < 0.001
Peripheral fat (kg) 18.2 (14.0–23.9) 16.3 (13.4–20.4) 24.7 (19.5–28.2) < 0.001
Peripheral fat/ASM ratio 1.1 ± 0.3 1.01 ± 0.20 1.36 ± 0.20 < 0.001
Functional Movement
Grip strength (kg) 19.6 ± 4.5 20.4 ± 4.3 17.6 ± 4.3 0.002
Grip strengthBMI (kg/m
2) 0.59 ± 0.18 0.63 (0.55–0.76) 0.48 (0.39–0.53) < 0.001
6-min walk (m) 450 (395–490) 462.5 (402.5–496.3) 405.0 (351.4–462.3) 0.010
Gait speed (m/sec) 1.53 (1.38–1.67) 1.55 (1.41–1.68) 1.46 (1.31–1.56) 0.022
3 m timed-up and go (sec) 6.9 (6.2–8.1) 6.7 (6.1–7.8) 7.2 (6.5–8.4) 0.057
All normally distributed and skewed data are reported as mean ± SD and Median (IQR – 25-75th percentile). Abbreviations: BMI Body mass index, FFSTM Fat-free
soft tissue mass, VAT visceral adipose tissue, SAT subcutaneous adipose tissue, ASM appendicular skeletal muscle mass, ASMI appendicular skeletal muscle mass
index, ASMBMI appendicular skeletal muscle mass adjust for body mass index, Grip strengthBMI Grip strength adjusted for body mass index
P values represent a significant difference between those with and without sarcopenia. Parametric and non-parametric (Mann-Whitney U) independent t-tests
were conducted on normally distributed and skewed data, respectively
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Table 3 Lifestyle behaviours, components of metabolic syndrome and sociodemographic characteristics of the cohort and those
with and without sarcopenia
Variables Cohort No sarcopenia Sarcopenia P value
Components of metabolic syndrome, inflammation, iron and vitamin D N = 121 N = 88 N = 33
Metabolic Syndrome n(%) 89 (73.0) 60 (68.2) 29 (85.3) 0.047
Waist Circumference (cm) 99.7 ± 15.1 97.1 ± 14.8 106.4 ± 13.7 0.002
Diastolic Blood Pressure (mmHg) 71.2 (64.7–78.9) 70.5 ± 12.1 74.3 ± 11.2 0.059
Systolic Blood Pressure (mmHg) 131.5 (118.9–172.7) 131.5 (119.1–148.4) 130.7 (117.7–146.0) 0.873
Glucose (mmol/L) 5.1 (4.8–6.4) 5.0 (4.7–6.4) 5.2 (4.8–6.2) 0.517
Triglycerides (mmol/L) 1.1 (0.8–1.6) 1.1 (0.8–1.6) 1.2 (1.0–1.8) 0.049
High-Density Lipoprotein (mmol/L) 1.3 (1.1–1.6) 1.3 (1.1–1.6) 1.3 (1.1–1.5) 0.440
C-Reactive Protein (mg/L)* 5.7 (2.2–8.7) 4.1 (1.9–7.4) 7.9 (4.2–12.8) < 0.001
Ferritin (ng/mL)* 112.1 (63.2–180.4) 127.2 (73.1–196.3) 85.0 (54.1–135.9) 0.014
Vitamin D-25OH (ng/mL) 13.0 (11.0–17.0) 13.0 (11.0–17.0) 13.0 (10.8–16.8) 0.771
Sociodemographics N = 122 N = 88 N = 34
Asset Index (n) 8 (6–9) 8 (6–9) 8 (6–9) 0.599
Children supported in household (n) 1 (0–3) 1 (0–2) 2 (1–3) 0.024
Housing Density 1.0 (0.6–1.4) 1.0 (0.6–1.3) 1.0 (0.6–1.8) 0.474
Food Insecurity (HFIAS) 6 (3–11) 7 (3–13) 6 (3–8) 0.088
Estimated Monthly Food Cost (US$) 90 (67–167) 90 (60–127) 93 (67–122) 0.738
Previous Smoker n(%) 5 (4.1) 2 (2.3) 3 (8.8) 0.036
Current Smoker n(%) 11 (9.0) 11 (12.5) 0 (0.0) 0.145
Physical activity and sedentary behaviour N = 116 N = 83 N = 33
Daily light PA (%) 37.1 ± 9.3 37.9 ± 9.8 35.0 ± 7.4 0.127
Daily MVPA (%) 1.0 (0.3–1.8) 1.0 (0.3–1.8) 0.95 (0.2–1.9) 0.765
Light PA (min/day) 326.2 ± 91.0 335.1 ± 94.9 303.4 ± 76.9 0.097
MVPA (min/day) 9.1 (2.3–15.9) 9.1 (2.5–15.9) 8.4 (1.4–15.8) 0.757
Daily Step count (n) 6848 (5122–8784) 7574 ± 3417 6037 ± 2431 0.020
Upright (min/day) 415.3 ± 125.9 422.8 ± 126.5 396.5 ± 124.5 0.312
Standing (min/day) 317.4 ± 107.0 319.6 ± 104.7 311.7 ± 114.2 0.720
Stepping (min/day) 97.9 ± 38.7 103.1 ± 40.9 84.8 ± 29.0 0.021
Sitting (min/day) 402.4 ± 113.4 401.1 ± 106.6 405.7 ± 130.7 0.973
Napping (min/day) 28.3 (0.0–64.1) 35.4 (0–67.4) 28.2 (13.7–51.8) 0.674
Sleeping (min/day) 568.6 (499.7–629.1) 566.1 (499.5–629.8) 582.3 (499.4–629.8) 0.592
Sitting bouts > 30min (n/day) 4 ± 1 4 ± 1 4 ± 2 0.414
Sitting bouts > 60min (n/day) 1 (1–2) 1 (1–1) 1 (1–2) 0.206
Sitting time > 30min (min/day) 213.8 ± 92.3 206.5 ± 84.6 232.3 ± 108.6 0.175
Sitting time > 60min (min/day) 92.8 (51.1–161.8) 89.5 (51.0–147.8) 104.7 (52.8–192.1) 0.259
Sit to stand transitions (n/day) 38 ± 12 40 (32–46) 33 (26–42) 0.007
Dietary intake: Macronutrients N = 103 N = 74 N = 29
Energy Intake (KJ) 7646 (5994–9991) 7870 (6057–10,361) 7462 (5903–8678) 0.278
Carbohydrates (%EI) 64.8 ± 7.2 64.8 ± 7.0 64.9 ± 7.7 0.940
Protein (%EI) 12.3 ± 2.1 12.3 ± 2.0 12.5 ± 2.5 0.648
Animal Protein (%EI) 5.8 ± 2.4 5.7 (4.0–7.7) 5.4 (4.1–7.7) 0.883
Plant Protein (%EI) 6.5 ± 1.5 6.4 (4.5–7.3) 6.3 (5.3–7.6) 0.797
Total Fat (%EI) 21.2 (17.5–25.1) 21.3 (17.4–25.1) 21.2 (17.1–24.3) 0.843
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test). This model shows a similar PA profile that identi-
fied those with sarcopenic obesity, with lower daily
MVPA and time spent upright as additional variables
that were associated with a lower grip strengthBMI. In
terms of dietary intake, consumption of cooked porridge
(%EI) correlated with a higher grip strengthBMI, while
consumption of animal protein foods (%EI), cholesterol
and fibre correlated with a lower grip strengthBMI.
Discussion
In this sample of older African women from a low-
income setting, we show a 27.9% prevalence of
Table 3 Lifestyle behaviours, components of metabolic syndrome and sociodemographic characteristics of the cohort and those
with and without sarcopenia (Continued)
Variables Cohort No sarcopenia Sarcopenia P value
PUFA (%EI) 5.7 (4.1–7.5) 5.7 (4.1–7.4) 5.7 (4.0–8.1) 0.889
MUFA (%EI) 6.7 (5.2–8.1) 6.7 (5.1–8.1) 6.6 (5.3–8.2) 0.982
Saturated Fat (%EI) 6.5 ± 2.2 6.5 ± 2.3 6.6 ± 2.2 0.901
Added sugar (%EI) 12.7 (8.6–18.0) 11.7 (8.4–18.1) 13.3 (9.0–18.0) 0.585
Cholesterol (g/4200 KJ) 73.7 (53.2–109.8) 72.7 (52.6–108.9) 88.4 ± 46.9 0.730
Fibre (g/4200 KJ) 14.1 (11.6–17.0) 14.1 (11.6–16.8) 13.9 (11.6–17.3) 0.708
Dietary intake: Food Groups N = 110 N = 81 N = 29
Milk and Dairy products (%EI) 7.2 (3.6–12.4) 7.8 (3.5–12.4) 7.0 (3.6–12.6) 0.585
Fats and oils (%EI) 3.4 (1.2–6.4) 3.5 (1.3–6.2) 3.0 (1.0–8.0) 0.916
Animal protein foods (%EI) 9.4 (5.7–13.6) 9.0 (5.5–13.1) 10.1 (6.1–14.9) 0.362
Fruit (%EI) 6.4 (3.0–11.1) 6.1 (3.0–10.8) 7.2 (2.9–13.6) 0.900
Vegetables (%EI) 2.6 (1.6–4.9) 2.6 (1.5–4.8) 2.4 (1.7–5.9) 0.585
Legumes (%EI) 1.7 (0.0–3.6) 1.8 (0.0–3.1) 1.5 (0.0–5.2) 0.758
Cooked Porridge (%EI) 8.4 (5.0–15.8) 9.0 (4.3–16.5) 7.8 (5.1–14.9) 0.732
Starchy grains (%EI) 31.1 ± 11.4 31.4 ± 10.7 30.1 ± 13.4 0.596
Savoury snacks, dishes and sauces (%EI) 0.8 (0.0–2.0) 0.8 (0.0–2.3) 0.7 (0.1–1.8) 0.948
Sugar and sugary foods (%EI) 14.9 (10.1–20.8) 14.8 (9.6–21.2) 15.1 (10.4–19.8) 0.922
Nuts and seeds (%EI) 0 (0–1.9) 0 (0–2.0) 0 (0–1.8) 0.905
Alcohol (%EI) 0 (0–0) 0 (0–0) 0 (0–0) 0.225
All normally distributed are reported as mean ± SD and and skewed data as median (IQR – 25-75th percentile). Abbreviation: HFIAS Household food insecurity
access scale, PA Physical activity, EI Energy intake, MVPA Moderate-to-vigorous physical activity, MUFA Monounsaturated fatty-acids. P values represent a
significant difference between those with and without sarcopenia. Parametric and non-parametric (Mann-Whitney U) independent t-tests were conducted on
normally distributed and skewed data, respectively. *CRP, cohort (n = 104), no sarcopenia (n = 73), sarcopenia (n = 33); Ferritin, cohort (n = 111), no sarcopenia (n =
81), sarcopenia (n = 33)
Table 4 History of falls and prevalence of chronic diseases and multimorbidity
Variables Cohort (n = 122) No sarcopenia (n = 88) Sarcopenia (n = 34) P value
Fallen in past year 46 (38.0) 34 (38.6) 12 (36.4) 0.819
Hypertension 105 (86.1) 72 (81.8) 33 (97.1) 0.029
Dyslipidemia 89 (73.0) 63 (71.6) 26 (81.3) 0.586
Diabetes 44 (36.1) 32 (32.7) 12 (35.3) 0.912
Arthritis 26 (21.3) 18 (20.5) 8 (23.5) 0.710
Osteoporosis 29 (23.8) 22 (25.0) 7 (20.6) 0.608
History of cancer 3 (2.5) 1 (1.1) 2 (5.9) 0.129
HIV 9 (7.4) 7 (8.0) 2 (5.9) 0.695
History of tuberculosis 22 (18.0) 19 (21.6) 3 (8.8) 0.100
Multi-morbidities (> 2 diseases) 111 (91.0) 81 (92.0) 30 (88.2) 0.501
All data reported as n (%). Chi-square was used to determine differences in frequency of each variable between those with and without sarcopenia. Abbreviation:
HIV human immunodeficiency virus
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Fig. 1 (See legend on next page.)
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sarcopenia, which comprises of 3.3% with sarcopenia
and 24.6% with sarcopenic obesity. This highlights that
both sarcopenia and obesity co-exist in this cohort, with
the FNIH criterion reporting a significantly higher
prevalence than when using other age and population
specific cut-points. These findings indicate a large dis-
crepancy in diagnostic criteria and the potential for sig-
nificantly underestimating the prevalence of sarcopenia
if an appropriate population-specific criterion is not ap-
plied and if BMI is not adjusted for. Furthermore, we
show that the main correlates that describe a profile of
sarcopenic obesity were lower food insecurity, low PA
and fitness, and a chronic inflammatory state; highlight-
ing the importance of addressing obesity within these
communities to prevent sarcopenic obesity and main-
taining quality of life with ageing.
The majority of women classified as sarcopenic
(27.9%) were also obese (88%). However, the current
study also shows that other criteria (EWGSOP, IWGS
and AWGS) present a prevalence of total sarcopenia
which ranged from 0.8–14.7%, which indicates the need
for a population-specific criterion that has not been
previously addressed in Africa. Importantly, the FNIH
criteria include data in African American cohorts and
were generated from data providing normative values for
grip strength and ASM when adjusting for BMI [12].
Previous findings have shown that sarcopenia defined
using methods considering both stature and fat mass are
better at predicting weakness, reduced physical function
and overall sarcopenia related disability than using
ASMI and grip strength methods alone [3, 6, 12, 13].
Given the high prevalence of obesity in the current
cohort (71%) and SA women (overweight and obesity of
~ 68%) [15, 16], this factor should not be ignored when
assessing sarcopenia in this setting. Indeed, these data
clearly indicate that FNIH BMI adjusted criteria may be
an optimal set of criteria [15, 16, 31]. Previous data using
the EWGSOP in SA women has shown a prevalence of
8.9% sarcopenia, however, this study included younger
(45+ years old) women with a BMI range of underweight
to overweight [27]. Using the same criteria (Table 1) our
cohort reports a prevalence of 14.7%. Furthermore, a
Gambian cohort of women between 40 and 75+ years,
with normal BMI (~ 22 kg/m2) reported a prevalence of
45% and 10% sarcopenia when applying FNIH and
EWGSOP criteria, respectively [7]. Notably, the FNIH
criteria have only been validated in adults over 65 years,
which is problematic when the mean life-expectancy of
South Africans is 65.1 years [29]. To reduce discrepan-
cies when reporting sarcopenia prevalence, African
population-specific criterion needs to be used, and obes-
ity adjusted for.
Sarcopenic obesity has been shown to exacerbate func-
tional limitations and cardiometabolic risk [6, 19]. The
current study showed that 38% of women reported that
they had fallen in the past year, compared to 26.4%
previously reported [52]. While a recent meta-analysis
identified a higher rate of falls and fractures in older
adults with sarcopenia [53], we show that those with sar-
copenia had lower cardiovascular fitness and gait speed,
but a similar prevalence of falls to those without sarco-
penia. We suggest that collecting information on the
number of falls may be more sensitive in detecting frailty
and risk of sarcopenia. Further, environmental context is
also important when understanding the mechanisms of
falls in low-income settings (poor infrastructure, over-
crowding and hazards in small dwellings) [52]. We also
showed that 91% of women had multimorbidity (> 2
chronic diseases), with the three most prevalent diseases
being hypertension (86%), dyslipidemia (73%) and type 2
diabetes (36%), which are all components of the meta-
bolic syndrome. Although hypertension was the only dis-
ease that was more prevalent in those with sarcopenia,
only waist circumference and triglycerides were the
metabolic syndrome components that discriminated be-
tween those with and without sarcopenic obesity. Our
results show that the high rate of chronic disease and
multi-morbidity is of concern in this cohort and is prob-
ably reflective of the high prevalence of obesity. This
demonstrates the need for targeting obesity and non-
communicable diseases in LMIC settings.
Low-grade chronic inflammatory status is associated
with obesity and sarcopenia and may represent increased
risk for developing cardiometabolic diseases [20, 22, 54].
The current study showed that higher levels of systemic
inflammation (as indexed by CRP) were associated with
sarcopenic obesity, which is supported by a recent meta-
analysis that showed that sarcopenia is associated with
higher CRP, but not with higher IL-6 or TNFα [22].
Notably, CRP was associated with lower grip strength,
but not muscle mass, which suggests that the inflamma-
tory contribution to sarcopenic obesity may reflect
(See figure on previous page.)
Fig. 1 Multivariate characteristic profile for non-sarcopenic and sarcopenic obese participants (n = 118; OPLS-DA CV-ANOVA P < 0.001). (a) OPLS-DA
cross-validated scores (tcv [1]) that describes participant variability in the characteristic profile. (b) The characteristic profile that discriminates between
non-sarcopenic and sarcopenic obese participants. The asterisk (*) represent variables that significantly (P < 0.05) discriminate between those with and
without sarcopenic obesity. Error bars represent 95% confidence intervals. All data in the OPLS-DA models are reported as loading weight (w [1]), which
describes the contribution of each listed variable (X variable) to the model
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muscle quality rather than quantity. Indeed, studies in
older men and women (> 60 years) reported that higher
baseline levels of IL-6 and CRP increased the risk for
loss of strength over 3 years [55]. Accordingly, higher
systemic concentrations of CRP may reflect higher adi-
posity in those with sarcopenia or sarcopenic obesity
[19]. Women have higher relative adipose tissue com-
pared to men and this may also explain previous data
showing an independent association between low grade
systemic inflammation (as indexed by CRP) and muscle
strength in older women, but not men [56].
Consequently, sarcopenia may originate from processes
such as age-related changes in body fat and body fat dis-
tribution, with the consequent low-grade chronic inflam-
matory state suggested to exacerbate progression of the
disease [22].
Our results showed that a more food secure environ-
ment and financially supporting more children were part
of the characteristic profile that described the sarcopenic
obese cohort. National data from SA reports that 26% of
the population regularly experience hunger and a further
28% are at risk of hunger, with access to food, household
income and social protection (i.e. social grants for child
support) all determining factors of food security [17].
Furthermore, socioeconomic status affects behavioural
(i.e. PA and diet) characteristics [17, 18]. The present
study shows an association between sarcopenic obesity
and increased food security, suggesting a higher socio-
economic status, but lower PA and higher sedentary be-
haviour profile. Although dietary variables did not
discriminate between those with and without sarcopenic
obesity, we paradoxically showed that those who had a
lower grip strength consumed more animal protein
foods and less cooked porridge. Although these findings
are difficult to explain, we hypothesise that either 1) the
animal protein foods were of poor quality (i.e. processed
meats, meat cuts with high fat content) and/or 2) those
sufficiently affluent to buy meat and animal based prod-
ucts did less daily PA, which may impact on strength.
However, longitudinal data is required to assess these
hypotheses. Specifically, additional sources of high-
quality protein that are sustainable, affordable and
Fig. 2 Multivariate associations between changes in BMI-adjusted grip
strength (FNIH criteria) and characteristics that relate to the
pathophysiology of sarcopenia (n = 121; OPLS CV-ANOVA P < 0.001).
(a) OPLS cross-validated scores (tcv [1]) that describes participant
variability and (b) multivariate associations in the characteristic profile
at the variable level. The asterisk (*) represent variables that are
significantly (P < 0.05) associated grip strength. Error bars represent
95% confidence intervals. All data in the OPLS models are reported as
loading weight (w [1]), which describes the contribution of each listed
variable (X variable) to the latent variable that is produced by the
model. Variables with large weights (w [1]) (positive or negative) are
highly correlated with grip strength
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culturally appropriate for low-income communities (i.e.,
red meat, poultry, fish, dairy, soy, nuts seeds and le-
gumes) in combination with a physically active lifestyle
may preserve muscle mass and function in older adults
[57, 58]. In a low-income setting, plant-based protein is
the most affordable source and further research is re-
quired to determine the effects it has on the overall pre-
vention of sarcopenia and sarcopenic obesity in these
high-risk communities.
Socioeconomic status within low-income communities
may influence PA patterns and overall cardiovascular
fitness [17, 18, 59]. Previous research in older adults in
highly developed countries have shown increased risk
for all-cause mortality with higher sedentary time [60],
and accumulating a higher percentage of sedentary time
in bouts of > 60min [61]. The current study showed that
increased sitting time in bouts of 60 min rather than
total daily sitting time were characteristics of the sarco-
penic obese participants and were related to a lower grip
strengthBMI. The odds of being abdominally obese in-
creases by 6.8% up to 48% for each 60 min sedentary
bout increment [62]. Therefore, sedentary behaviour
may also reflect higher levels of adiposity rather than
sarcopenia per se. Regardless, higher adiposity in the
current study was clearly associated with characteristics
of sarcopenia. When considering the impact of sedentary
behaviour on health-related outcomes, time spent being
physically active, regardless of intensity also needs to be
considered [60]. Importantly, a maximal risk reduction
for all-cause mortality in older adults is observed at 7500
steps/day, 375 min/day of light PA, or 24 min/day of
MVPA [60, 63]. In the present study, the mean daily step
count of those without sarcopenia (7574 steps/day) was
above the daily recommended step count for older
adults, while those with sarcopenia were below, with a
mean daily step count of 6037 steps/day. Although both
groups were below the recommended light PA and
MVPA recommendations, the sarcopenic group spent ~
30min/day less time in total MVPA and light PA com-
pared to those without sarcopenia. Accordingly, our re-
sults suggest that increasing PA, while interrupting
sedentary time can be collectively targeted for
intervention-based research for the overall prevention of
sarcopenic obesity.
Limitations
The current study presents several limitations that need
to be considered when interpreting the results. The
cross-sectional nature of the study does not allow an
assessment of causation. Thus, longitudinal and inter-
ventional studies are required in this population to
extend the current descriptive findings. Although the
HFIAS has been validated for use in South Africa, limita-
tions with the access component of the questionnaire
have been identified and expectations of possible finan-
cial or food aid influence results towards a more affirma-
tive response [64]. The convenience sampling included
few sarcopenic participants without obesity; however,
the obesity prevalence reflects national data of older SA
women, but these data may not be reflective of women
in SA without obesity. Further, this study attempted to
recruit an equal number of men and women, however
there were major challenges with the recruitment, reten-
tion and compliance of the men, resulting in the captur-
ing of incomplete data on only n = 25 men. This is
common in epidemiological studies in SA and represent
a significant limitation to the present study and current
literature [65, 66]. Accordingly, these data can only be
extrapolated to older black SA women. Larger cohort
studies are required across Africa to understand the bur-
den that sarcopenia and sarcopenic obesity may pose on
the ageing population in LMIC.
Conclusions
Collectively, we propose that the criterion presented by
the FNIH is a feasible option for classifying sarcopenia
in older, obese African women. The high prevalence of
sarcopenia, obesity and multimorbidity demonstrate the
need for sustainable interventions in these communities
to reduce the burden on the health care system and to
ensure that quality of life is maintained with ageing.
Accordingly, targeting PA and dietary behaviours at a
younger age should be a focus in LMIC to not only
prevent obesity related multi-morbidities, but also
sarcopenia.
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